Do you want to read an article? Please log in or register.
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Related content
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Int J Cardiol.
Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B
doi: 10.1016/j.ijcard.2016.08.273.
Diabetes - GeneralLipids
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
Diabetes Obes Metab.
Ganda OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, Koren A, Mandel J, Letierce A, Leiter LA
doi: 10.1111/dom.13384.
COMMENTED
Diabetes - General
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Lancet Diabetes Endocrinol.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG, ODYSSEY OUTCOMES Committees and Investigators.
doi: 10.1016/S2213-8587(19)30158-5.
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Circulation.
Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN
doi: 10.1161/
Diabetes - GeneralType 1 Diabetes
Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial
Neurology.
Lewis EJH, Perkins BA, Lovblom LE, Bazinet RP, Wolever TMS, Bril V
doi: 10.1212/
COMMENTED
Type 2 Diabetes
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT
doi: 10.1016/S0140-6736(21)01324-6
COMMENTED
Clinical Nutrition
Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial
★ 3
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
JAMA
Bischoff-Ferrari HA, Vellas B, Rizzoli R, Kressig RW, da Silva JAP, Blauth M, Felson DT, McCloskey EV, Watzl B, Hofbauer LC, Felsenberg D, Willett WC, Dawson-Hughes B, Manson JE, Siebert U, Theiler R, Staehelin HB, de Godoi Rezende Costa Molino C, Chocano-Bedoya PO, Abderhalden LA, Egli A, Kanis JA, Orav EJ, DO-HEALTH Research Group.
doi: 10.1001/jama.2020.16909
Glycemic Control
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials
Cardiovasc Diabetol
Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S
doi: 10.1186/s12933-021-01291-w
Diabetes - GeneralType 2 Diabetes
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
Diabetologia
Sen T, Li J, Neuen BL, Neal B, Arnott C, Parikh CR, Coca SG, Perkovic V, Mahaffey KW, Yavin Y, Rosenthal N, Hansen MK, Heerspink HJL
doi: 10.1007/s00125-021-05512-5